$HUGE News

Last published 1y ago

1y agoHUGE MDCX QNTMQuantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza BokhariGlobeNewswireTORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), announced today that the Company and Dr. Raza Bokhari, Company's former
1y agoHUGE QNTMQuantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for OntarioGlobeNewswireTORONTO, April 14, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ:QNTM) (CSE:QNTM) (FRA: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a
1y agoHUGE QNTMQuantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation UpdatesACCESS NewswireAwards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. ("Quantum
1y agoHUGE QNTMQuantum BioPharma Previously Known as FSD Pharma (Nasdaq:HUGE) (CSE:HUGE) Invites Shareholders to Come Forward and Join Hands With the Company in the US700M$+ Court Case the Company Has Filed Against CIBC, RBC, and Others for Alleged Spoofing/Stock Price ManipulationACCESS NewswireTORONTO, ON / ACCESSWIRE / November 25, 2024 / Quantum BioPharma Ltd. formerly named FSD Pharma Inc. is pleased to follow up on recent
2y agoHUGE QNTMQuantum Biopharma Announces Intention to Complete Debt Settlements and Provides Corporate UpdateACCESS NewswireTORONTO, ON / ACCESSWIRE / August 23, 2024 / Quantum BioPharma Ltd. , a biopharmaceutical company
2y agoHUGEFSD Pharma Provides Update on its Investment in Celly Nutrition Corp. Who Secures Additional Financing to Launch unbuzzd(TM) Stick Packs this Month - Created by a World-Class Pharmaceutical Research & Development TeamACCESS NewswireTORONTO, ON / ACCESSWIRE / August 9, 2024 / FSD Pharma Inc. , provides an update on its investment in Celly Nutrition Corp. , a privately
2y agoHUGEFSD Pharma provides Corporate UpdateACCESS NewswireTORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma, Inc. Wins Final Judgment to Confirm Arbitration Award of $3,059,998 Plus Interest Entered Against Dr. Raza Bokhari, Currently Serving as Chairman and CEO of Medicus Pharma Ltd.ACCESS NewswireTORONTO, ON / ACCESSWIRE / June 28, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in AustraliaACCESS NewswireTORONTO, ON / ACCESSWIRE / June 27, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma Enters Into an Exclusive Option Agreement With the University of Southern California To Evaluate Novel Dietary Supplement Technology for unbuzzd(TM) and Other Business ApplicationsACCESS NewswireTORONTO, ON / ACCESSWIRE / June 13, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol IntoxicationACCESS NewswireTORONTO, ON / ACCESSWIRE / June 4, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma, Inc. Wins Petition to Confirm Arbitration Awards Entered Against Dr. Raza Bokhari Totaling Over $3 Million CAD, Plus InterestACCESS NewswireTORONTO, ON / ACCESSWIRE / May 31, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma Submits a Clinical Trial Protocol to Study the Safety and Efficacy of Unbuzzd(TM) in Acute Alcohol IntoxicationACCESS NewswireTORONTO, ON / ACCESSWIRE / May 28, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech
2y agoHUGEFSD Pharma Provides Corporate UpdateACCESS NewswireTORONTO, ON / ACCESSWIRE / May 24, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Provides Update on Celly Nu's New Packaging for unbuzzd(TM)ACCESS NewswireTORONTO, ON / ACCESSWIRE / May 16, 2024 / FSD Pharma Inc. , provides an update by way of a news release issued by Celly Nutrition Corp. ,
2y agoHUGEFSD Pharma Submits a Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in AustraliaACCESS NewswireTORONTO, ON / ACCESSWIRE / May 7, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of innovative
2y agoHUGEFSD Pharma Signs Agreement with Applied Science and Performance Institute (ASPI) to Conduct a Clinical Trial in the United States to Assess the Safety and Efficacy of unbuzzd(TM) in an Induced State of Alcohol IntoxicationACCESS NewswireTORONTO, ON / ACCESSWIRE / April 30, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Provides Update from Celly Nu's Partnership with Six+One for unbuzzd(TM)ACCESS NewswireTORONTO, ON / ACCESSWIRE / April 25, 2024 / FSD Pharma Inc. , provides an update by way of a news release issued by Celly Nutrition Corp. ,
2y agoHUGEFSD Pharma Provides Another Update on Celly Nu's Anticipated Launch of unbuzzd(TM)ACCESS NewswireTORONTO, ON / ACCESSWIRE / April 22, 2024 / FSD Pharma Inc. , provides an update by way of a news release issued by Celly Nutrition Corp. ,
2y agoHUGEFSD Pharma Expands Investigative Pipeline to Include Potential Weight Loss and Liver Health Formulations and ProductsACCESS NewswireTORONTO, ON / ACCESSWIRE / April 17, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Provides Update on its Investment in Celly Nutrition Corp., a Company Launching a Product that can assist in Expediting Alcohol Metabolism and Faster Recovery from Alcohol ConsumptionACCESS NewswireTORONTO, ON / ACCESSWIRE / April 15, 2024 / FSD Pharma Inc. , provides an update on its investment in Celly Nutrition Corp. , a privately
2y agoHUGEFSD Pharma Announces Filing of Year-End 2023 ResultsACCESS NewswireTORONTO, ON / ACCESSWIRE / April 1, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Signs the Agreement With iNGENu CRO To Conduct a Clinical Study To Assess the Safety and Pharmacokinetics of Multiple Ascending Doses of Lucid-21-302 (Lucid-MS) in Healthy AdultsACCESS NewswireTORONTO, ON / ACCESSWIRE / March 27, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Presents Positive Results on First-In-Human Phase-1 study of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 2024 ForumACCESS NewswireTORONTO, ON / ACCESSWIRE / March 5, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Announces Debt SettlementACCESS NewswireTORONTO, ON / ACCESSWIRE / February 28, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Signs Agreement With Ingenu CRO to Conduct a Clinical Trial To Determine the Safety and Efficacy Effects of its Proprietary Blend Beverage unbuzzd(TM)ACCESS NewswireTORONTO, ON / ACCESSWIRE / February 26, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Announces US ATM OfferingACCESS NewswireTORONTO, ON / ACCESSWIRE / February 16, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGECourt of Appeal Dismisses Motion for Leave to Appeal Brought by Dr. Raza Bokhari, FSD Pharma Awards Total Approximately $3 MillionACCESS NewswireTORONTO, ON / ACCESSWIRE / February 6, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Announces Dr. Sanjiv Chopra is elected to FSD Pharma Board of Directors and Corporate UpdatesACCESS NewswireTORONTO, ON / ACCESSWIRE / January 29, 2024 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGE SHOTUpdate Provided on GBB Drink Lab, Inc. Litigation and Safety ShotACCESS NewswireTORONTO, ON / ACCESSWIRE / January 16, 2024 / FSD Pharma Inc. , is a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEGBB Maintains Strong Position in its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss CaseGlobeNewswireWESTON, Fla., Jan. 11, 2024 (GLOBE NEWSWIRE) -- GBB Drink Lab. Inc ("GBB" or the "Company"), a maker of the world's first rapid blood alcohol detoxification beverage, is pleased to announce that a federal court has
2y agoHUGEFSD Pharma Files Final Base Shelf Prospectus to Replace Expired Base Shelf Prospectus and Form F-3 Registration Statement with the SECACCESS NewswireTORONTO, ON / ACCESSWIRE / December 22, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Inc. Announces Closing of Private PlacementACCESS NewswireTORONTO, ON / ACCESSWIRE / December 5, 2023 / FSD Pharma Inc. , is pleased to announce that, further to its news release on November 27, 2023,
2y agoHUGEFSD Pharma Inc. and Celly Nutrition Corp. Announce Completion of Plan of ArrangementACCESS NewswireTORONTO, ON / ACCESSWIRE / November 30, 2023 / FSD Pharma Inc. and Celly Nutrition Corp. are pleased to announce the
2y agoHUGE SHOT JUPWUpdate Provided on GBB Drink Lab, Inc. Litigation and Safety Shot Previously known as Jupiter WellnessACCESS NewswireTORONTO, ON / ACCESSWIRE / November 28, 2023 / FSD Pharma Inc. , is a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Inc. Obtains Final Order for Plan of ArrangementACCESS NewswireTORONTO, ON / ACCESSWIRE / November 27, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEGoldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.ACCESS NewswireBALTIMORE, MD / ACCESSWIRE / November 24, 2023 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has published a new research report on
2y agoHUGEFSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.ACCESS NewswireTORONTO, ON / ACCESSWIRE / November 21, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Announces Distribution Date for Distribution of Celly Shares Pursuant to Plan of ArrangementACCESS NewswireTORONTO, ON / ACCESSWIRE / November 17, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
2y agoHUGEFSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023ACCESS NewswireTORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma Provides Update on Proposed Dividend Distribution for Shareholders of FSD Pharma to Receive Shares of Celly Nutrition on a One for One BasisACCESS NewswireTORONTO, ON / ACCESSWIRE / November 7, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf ProspectusACCESS NewswireTORONTO, ON / ACCESSWIRE / November 6, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma Files Management Information Circular for Proposed Arrangement with Celly NuACCESS NewswireTORONTO, ON / ACCESSWIRE / October 23, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma and Celly Nu Enter Into Arrangement AgreementACCESS NewswireTORONTO, ON / ACCESSWIRE / October 5, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of JusticeACCESS NewswireTORONTO, ON / ACCESSWIRE / October 4, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEInvestmentPitch Media Video Discusses FSD Pharma's Continued Development of its Exciting New Rapid Detox Drink UNBUZZD™, with Video Comments from Kevin HarringtonGlobeNewswireVANCOUVER, British Columbia, Sept. 22, 2023 (GLOBE NEWSWIRE) -- FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a biotechnology company building a portfolio of innovative assets and biotech solutions for the
3y agoHUGEFSD Pharma announces Interim Results from First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis; The Report Shows Compound to be Safe and Well ToleratedACCESS NewswireTORONTO, ON / ACCESSWIRE / September 18, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoHUGEFSD Pharma Announces Analyst Coverage Initiated by Singular ResearchACCESS NewswireTORONTO, ON / ACCESSWIRE / September 13, 2023 / FSD Pharma Inc. , a biopharmaceutical company dedicated to building a portfolio of
3y agoCSE:HUGE HUGE JUPWFSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)Business WireFSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of
3y agoHUGEFSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023ACCESS NewswireTargeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment MarketTORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. ("FSD Pharma" or the